References
- Westin J, Aleman S, Castedal M, et al. Management of hepatitis B virus infection, updated Swedish guidelines. Infect Dis. 2019;15:1–22.
- Park H, Kim DY, Kim SJ, et al. HBsAg-negative, anti-hbc-negative patients still have a risk of hepatitis B virus-related hepatitis after autologous stem cell transplantation for multiple myeloma or malignant lymphoma. Cancer Res Treat. 2018;50(4):1121–1129.
- Avettand-Fenoel V, Thabut D, Katlama C, et al. Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol. 2006;44(6):2250–2253.
- Lee S-D, Lo K-J, Tsai Y-T, et al. HBsAg carrier infants with serum anti-HBc negativity. Hepatology. 1989;9(1):102–104.
- Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
- Buonomo AR, Zappulo E, Viceconte G, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17(7):709–717.
- Zappulo E, Buonomo AR, Saccà F, et al. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis. 2019;6(11):ofz445.
- Ciardi MR, Iannetta M, Zingaropoli MA, et al. Reactivation of Hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis. 2019;6(1):1–3.
- Shiota G, Harada K, Oyama K, et al. Severe exacerbation of hepatitis after short-term corticosteroid therapy in a patient with ‘latent’ chronic hepatitis B. Liver Int. 2000;20(5):415–420.